ROR1 and neoplasm: A study, performed recently, involving ROR1 CAR-T cells with inducible anti-PD-1 single-chain variable fragments (scFv) in TNBC models demonstrated enhanced tumor control, indicating a potential synergistic effect between PD-1 blockade and engineered T cells [253].